How many primary biliary cholangitis (PBC) patients do you have in your clinic?

What percent of your patients are "biochemical responders" to UDCA monotherapy (definition of biochemical responder: alkaline phosphatase (ALP) is <1.67x the ULN after treatment with UDCA)?

Of all the PBC patients you treat, what percent of them get ALP below 1.67x the upper limit of normal on UDCA alone, but still have ALP above normal?

What percent of your patients are on Ocaliva?

What is the most common reason for patients who are not biochemically responding to UDCA alone to NOT be on Ocaliva as a second line treatment? Select one.

• Insurance coverage/copay issues
• Patient refusal to start- fear of worsening itch
• Patient discontinuation- actual worsening itch
• Safety/DILI concerns
• Patient is contraindicated (cirrhotic or has portal hypertension)
• Other (please specify) /OE/

For all of your patients on UDCA alone, what percent experience any itch at all?

For all of your patients on UDCA alone, what percent experience an itch that is clinically impactful/impairs their quality of life?

If seladelpar and elafibranor are approved in PBC, what percent of your patients who are not responding to UDCA alone will be taking any PPAR agonist within 1 year of approval?

If seladelpar and elafibranor are approved in PBC, what percent of your patients who are not responding to UDCA alone will be taking either of these drugs within 3 years of approval?

If seladelpar and elafibranor are both approved in PBC, what percent of your patients on PPAR agonists will be on elafibranor versus seladalpar?

• Elafibranor:
• Seladalpar:

Please provide your rationale for your answer to question above.

Please rank the following 3 treatments for 2L PBC, with 1 being your favorite and 3 being your least favorite:

• Elafibranor:
• Seladalpar:
• Ocaliva:

Do you expect a change in the guidelines to target normal ALP instead of using 1.67x ULN as a responder threshold? Why?

Describe if/how you would use 2L agents off-label in patients with ALP between 1-1.67x ULN.

What other drugs are you excited about that are in development for any of the conditions you treat (doesn't have to be PBC)?